Virpax Pharmaceuticals (NASDAQ: VRPX) specializes in developing novel and proprietary drug delivery systems across various pain indications to enhance compliance and optimize the ability of each ...

Virpax gains after extending its partnership with NCATS to advance NES100, a novel intranasal peptide for pain management. NES100 uses nanotechnology to deliver enkephalin to the brain, potentially ...

Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Oil & Gas, Technology and Industrials sectors... Investing.com -- Virpax Pharmaceuticals Inc . (NASDAQ:VRPX) shares ...

Virpax Pharmaceuticals (NASDAQ:VRPX) just reported results for the fourth quarter of 2023. Virpax Pharmaceuticals reported earnings per share of -$3.87. This was below the analyst estimate for EPS of ...

Virpax Pharmaceuticals (NASDAQ:VRPX) just reported results for the first quarter of 2024. Virpax Pharmaceuticals reported earnings per share of -$2.75. The company did not report any revenue for the ...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX), that sends out ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings with ...

Dividend history information is presently unavailable for this company. This could indicate that the company has never provided a dividend or that a dividend is pending. Nasdaq Data provided by Nasdaq ...